Skip to Content

Drug interactions between Caltrate 600+D and Caltrate 600 Plus

Results for the following 2 drugs:
Caltrate 600+D (calcium/vitamin d)
Caltrate 600 Plus (multivitamin with minerals)

Interactions between your drugs


ergocalciferol multivitamin with minerals

Applies to: Caltrate 600+D (calcium / vitamin d) and Caltrate 600 Plus (multivitamin with minerals)

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Due to a narrow therapeutic index, vitamin D analogs given in combination with each other or with pharmacologic doses of vitamin D may demonstrate additive effects resulting in toxicity manifested as hypercalcemia, hypercalciuria, and hyperphosphatemia. Progressive hypercalcemia due to overdosage of vitamin D and its metabolites can be dangerous and sufficiently severe as to require emergency attention. Acute hypercalcemia may exacerbate tendencies for cardiac arrhythmias and seizures and may potentiate the action of digitalis drugs. Chronic hypercalcemia can lead to generalized vascular calcification, nephrocalcinosis, and calcifications of the cornea or other soft tissues. Immobilized patients are particularly vulnerable to the risk of hypercalcemia.

MANAGEMENT: Vitamin D analogs should not be used in combination with each other or with pharmacologic doses of vitamin D. Serum calcium and phosphorus levels must be closely monitored during therapy with a vitamin D analog, especially early in treatment during dosage adjustment. The serum calcium X phosphorus product should be maintained at less than 55 in patients with chronic kidney disease and should not be allowed to exceed 70 in any patient. An estimate of daily dietary calcium intake should be made and the intake adjusted when indicated. Patients should be advised to avoid an abrupt increase in dietary calcium intake, as it may trigger hypercalcemia, and to contact their physician if they experience early symptoms of vitamin D intoxication associated with hypercalcemia such as weakness, fatigue, headache, somnolence, vertigo, tinnitus, anorexia, nausea, vomiting, constipation, dry mouth, metallic taste, muscle pain, bone pain, ataxia, and hypotonia. Late symptoms may include polyuria, polydipsia, weight loss, nocturia, conjunctivitis, photophobia, rhinorrhea, pruritus, hyperthermia, decreased libido, and cardiac arrhythmias. Radiographic evaluation of suspect anatomical regions may be useful in the early detection of hypercalcemia. If hypercalcemia develops, treatment with vitamin D and any calcium product should be stopped immediately.


  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Hectorol (doxercalciferol)." Genzyme Corporation, Cambridge, MA.
  3. "Product Information. One-Alpha (alfacalcidol)." Pharmel Inc, Montreal, IN.
  4. "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.
  5. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
View all 5 references

Drug and food interactions

No results found in our database - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.